October 31, 2019 / 7:25 AM / 20 days ago

CORRECTED-BRIEF-Swedish Orphan Biovitrum Q3 EBITA Up At SEK 1.10 Bln

(Corrects number in headline to SEK 1.10 bln from SEK 1.01 bln.)

Oct 31 (Reuters) - Swedish Orphan Biovitrum AB (publ) :

* Q3 EBITA WAS SEK 1,099 M (933)

* Q3 SALES FOR ELOCTA WERE SEK 1,156 M (873) AND SALES FOR ALPROLIX WERE SEK 341 M (255)

* “OUR GROWTH JOURNEY CONTINUED IN Q3, STRENGTHENING OUR HAEMATOLOGY FRANCHISE WITH ANNOUNCEMENTS OF INTENTION TO ACQUIRE DOVA PHARMACEUTICALS1AND OUR DECISION TO OPT IN EARLY TO DEVELOPMENT OF BIVV001” CEO

* NET DEBT OF SEK 7,606 M AT 30 SEPTEMBER 2019 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below